Stem cell-like side populations in esophageal cancer: A source of chemotherapy resistance and metastases

Stem Cells and Development

Volumn 23, Issue 2, 2014, Pages 180-192

  Zhao, Yue ^a,b   Bao, Qi ^a   Schwarz, Bettina ^a   Zhao, Lu ^a   Mysliwietz, Josef ^c   Ellwart, Joachim ^c   Renner, Andera ^a   Hirner, Heidrun ^a   Niess, Hanno ^a   Camaj, Peter ^a   Angele, Martin ^a   Gros, Stephanie ^d   Izbicki, Jakob ^d   Jauch, Karl Walter ^a   Nelson, Peter Jon ^a   Bruns, Christiane J ^e  

^a UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY OF HAMBURG   (Germany)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ABC TRANSPORTER A2; ABC TRANSPORTER A3; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; VERAPAMIL; VIMENTIN; ABCB1 PROTEIN, HUMAN; ABCG2 PROTEIN, HUMAN; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BETA CATENIN; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CARCINOGENICITY; CARCINOMA CELL; CELL POPULATION; CELL VIABILITY; COLONY FORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LONG TERM EXPOSURE; MALE; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STEM CELL; STEM CELL LIKE SIDE POPULATION; SYSTEMIC DISEASE; UPREGULATION; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER STEM CELL; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CYTOLOGY; DRUG RESISTANCE; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION; NUDE MOUSE; PATHOLOGY; SIDE POPULATION CELL; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BETA CATENIN; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CELL LINE, TUMOR; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; EPITHELIAL-MESENCHYMAL TRANSITION; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; SIDE-POPULATION CELLS; THYMIDYLATE SYNTHASE;

EID: 84891838511     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0103     Document Type: Article

References (69)

1. Jemal A, R Siegel, E Ward, T Murray, J Xu and MJ Thun. (2007). Cancer statistics, 2007. CA Cancer J Clin 57:43-66.
2. Devesa SS, WJ Blot and JF Fraumeni, Jr. (1998). Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83:2049-2053.
3. Rice TW, DJ Adelstein, G Zuccaro, GW Falk and JR Goldblum. (1997). Advances in the treatment of esophageal carcinoma. Gastroenterologist 5:278-294.
4. Maugeri-Sacca M, P Vigneri and R De Maria. (2011). Cancer stem cells and chemosensitivity. Clin Cancer Res 17:4942-4947.
5. Lapidot T, C Sirard, J Vormoor, B Murdoch, T Hoang, J Caceres-Cortes, M Minden, B Paterson, MA Caligiuri and JE Dick. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645-648.
6. Al-Hajj M, MS Wicha, A Benito-Hernandez, SJ Morrison and MF Clarke. (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988.
7. Singh SK, ID Clarke, M Terasaki, VE Bonn, C Hawkins, J Squire and PB Dirks. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821-5828.
8. Schatton T, GF Murphy, NY Frank, K Yamaura, AM Waaga-Gasser, M Gasser, Q Zhan, S Jordan, LM Duncan, et al. (2008). Identification of cells initiating human melanomas. Nature 451:345-349.
9. Szotek PP, R Pieretti-Vanmarcke, PT Masiakos, DM Dinu-lescu, D Connolly, R Foster, D Dombkowski, F Preffer, DT Maclaughlin and PK Donahoe. (2006). Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 103:11154-11159.
10. Prince ME, R Sivanandan, A Kaczorowski, GT Wolf, MJ Kaplan, P Dalerba, IL Weissman, MF Clarke and LE Ailles. (2007). Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104:973-978.
11. Kim CF, EL Jackson, AE Woolfenden, S Lawrence, I Babar, S Vogel, D Crowley, RT Bronson and T Jacks. (2005). Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121:823-835.
12. Ricci-Vitiani L, DG Lombardi, E Pilozzi, M Biffoni, M Todaro, C Peschle and R De Maria. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature 445:111-115.
13. Li C, DG Heidt, P Dalerba, CF Burant, L Zhang, V Adsay, M Wicha, MF Clarke and DM Simeone. (2007). Identification of pancreatic cancer stem cells. Cancer Res 67:1030-1037.
14. Houghton J, C Stoicov, S Nomura, AB Rogers, J Carlson, H Li, X Cai, JG Fox, JR Goldenring and TC Wang. (2004). Gastric cancer originating from bone marrow-derived cells. Science 306:1568-1571.
15. Wu PC, VC Lai, JW Fang, MA Gerber, CL Lai and JY Lau. (1999). Hepatocellular carcinoma expressing both hepato-cellular and biliary markers also expresses cytokeratin 14, a marker of bipotential progenitor cells. J Hepatol 31:965-966.
16. Haraguchi N, H Inoue, F Tanaka, K Mimori, T Utsunomiya, A Sasaki and M Mori. (2006). Cancer stem cells in human gastrointestinal cancers. Hum Cell 19:24-29.
17. Zhou S, JD Schuetz, KD Bunting, AM Colapietro, J Sampath, JJ Morris, I Lagutina, GC Grosveld, M Osawa, H Nakauchi and BP Sorrentino. (2001). The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7:1028-1034.
18. Haraguchi N, T Utsunomiya, H Inoue, F Tanaka, K Mimori, GF Barnard and M Mori. (2006). Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24:506-513.
19. Doyle L and DD Ross. (2003). Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340-7358.
20. Kabashima A, H Higuchi, H Takaishi, Y Matsuzaki, S Suzuki, M Izumiya, H Iizuka, G Sakai, S Hozawa, T Azuma and T Hibi. (2009). Side population of pancreatic cancer cells predominates in TGF-beta-mediated epithelial to mesen-chymal transition and invasion. Int J Cancer 124:2771-2779.
21. Zhou J, CY Wang, T Liu, B Wu, F Zhou, JX Xiong, HS Wu, J Tao, G Zhao, M Yang and SM Gou. (2008). Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J Gastroenterol 14:925-930.
22. Foster AE, FV Okur, E Biagi, A Lu, G Dotti, E Yvon, B Savoldo, G Carrum, MA Goodell, HE Heslop and MK Brenner. (2010). Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia 24:563-572.
23. Woodward WA, MS Chen, F Behbod, MP Alfaro, TA Buchholz and JM Rosen. (2007). WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 104:618-623.
24. Ma S, KW Chan, L Hu, TK Lee, JY Wo, IO Ng, BJ Zheng and XY Guan. (2007). Identification and characterization of tu-morigenic liver cancer stem/progenitor cells. Gastro-enterology 132:2542-2556.
25. Hosch S, J Kraus, P Scheunemann, JR Izbicki, C Schneider, U Schumacher, K Witter, MR Speicher and K Pantel. (2000). Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer. Cancer Res 60:6836-6840.
26. Pantel K, A Dickmanns, A Zippelius, C Klein, J Shi, W Hoechtlen-Vollmar, G Schlimok, D Weckermann, R Ober-neder, E Fanning, et al. (1995). Establishment of micro-metastatic carcinoma cell lines: a novel source of tumor cell vaccines. J Natl Cancer Inst 87:1162-1168.
27. Ischenko I, P Camaj, H Seeliger, A Kleespies, M Guba, EN De Toni, B Schwarz, C Graeb, ME Eichhorn, KW Jauch and CJ Bruns. (2008). Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling. Oncogene 27:7212-7222.
28. Shi GM, Y Xu, J Fan, J Zhou, XR Yang, SJ Qiu, Y Liao, WZ Wu, Y Ji, et al. (2008). Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol 134:1155-1163.
29. Wang J, LP Guo, LZ Chen, YX Zeng and SH Lu. (2007). Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 67:3716-3724.
30. Daly JM, WA Fry, AG Little, DP Winchester, RF McKee, AK Stewart and AM Fremgen. (2000). Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 190:562-572; discussion 572-573.
31. Enzinger PC and RJ Mayer. (2003). Esophageal cancer. N Engl J Med 349:2241-2252.
32. Parkin DM, P Pisani and J Ferlay. (1999). Global cancer statistics. CA Cancer J Clin 49:33-64.
33. Cunningham D, N Starling, S Rao, T Iveson, M Nicolson, F Coxon, G Middleton, F Daniel, J Oates and AR Norman. (2008). Capecitabine and oxaliplatin for advanced esopha-gogastric cancer. N Engl J Med 358:36-46.
34. Thallinger CM, M Raderer and M Hejna. (2011). Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol 29:4709-4714.
35. Levina V, AM Marrangoni, R DeMarco, E Gorelik and AE Lokshin. (2008). Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3:e3077.
36. Chikazawa N, H Tanaka, T Tasaka, M Nakamura, M Ta-naka, H Onishi and M Katano. (2010). Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res 30:2041-2048.
37. Yu F, H Yao, P Zhu, X Zhang, Q Pan, C Gong, Y Huang, X Hu, F Su, J Lieberman and E Song. (2007). let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109-1123.
38. Moserle L, M Ghisi, A Amadori and S Indraccolo. (2010). Side population and cancer stem cells: therapeutic implications. Cancer Lett 288:1-9.
39. Dean M, T Fojo and S Bates. (2005). Tumour stem cells and drug resistance. Nat Rev Cancer 5:275-284.
40. Wu C and BA Alman. (2008). Side population cells in human cancers. Cancer Lett 268:1-9.
41. Donnenberg VS and AD Donnenberg. (2005). Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 45:872-877.
42. Che SM, XZ Zhang, XL Liu, X Chen and L Hou. (2011). The radiosensitization effect of NS398 on esophageal cancer stem cell-like radioresistant cells. Dis Esophagus 24:265-273.
43. Zhang X, R Komaki, L Wang, B Fang and JY Chang. (2008). Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res 14:2813-2823.
44. Abdullah LN and EK Chow. (2013). Mechanisms of che-moresistance in cancer stem cells. Clin Transl Med 2:3.
45. Zhou S, JJ Morris, Y Barnes, L Lan, JD Schuetz and BP Sorrentino. (2002). Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci USA 99:12339-12344.
46. Jaggupilli A and E Elkord. (2012). Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol 2012:708036.
47. Gong C, H Yao, Q Liu, J Chen, J Shi, F Su and E Song. (2010). Markers of tumor-initiating cells predict chemoresistance in breast cancer. PLoS One 5:e15630.
48. Chai LX, KL Sun, LP Guo, HT Zhang and SX Lu. (2007). [Expression of ezrin and CD44-v6 in human esophageal squamous cell carcinoma and its clinical significance]. Zhonghua Zhong Liu Za Zhi 29:685-688.
49. Takayama N, S Arima, S Haraoka, T Kotho, K Futami and A Iwashita. (2003). Relationship between the expression of adhesion molecules in primary esophageal squamous cell carcinoma and metastatic lymph nodes. Anticancer Res 23:4435-4442.
50. Bertolini G, L Roz, P Perego, M Tortoreto, E Fontanella, L Gatti, G Pratesi, A Fabbri, F Andriani, et al. (2009). Highly tumorigenic lung cancer CD133+cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106:16281-16286.
51. Mueller MT, PC Hermann, J Witthauer, B Rubio-Viqueira, SF Leicht, S Huber, JW Ellwart, M Mustafa, P Bartenstein, et al. (2009). Combined targeted treatment to eliminate tu-morigenic cancer stem cells in human pancreatic cancer. Gastroenterology 137:1102-1113.
52. Mizrak D, M Brittan and MR Alison. (2008). CD133: molecule of the moment. J Pathol 214:3-9.
53. Li Y, B Welm, K Podsypanina, S Huang, M Chamorro, X Zhang, T Rowlands, M Egeblad, P Cowin, et al. (2003). Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci USA 100:15853-15858.
54. Martelli AM, C Evangelisti, F Chiarini, C Grimaldi, A Cap-pellini, A Ognibene and JA McCubrey. (2010). The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelo-poiesis and leukemogenesis. Biochim Biophys Acta 1803: 991-1002.
55. Hsu PK, AF Li, YC Wang, CC Hsieh, MH Huang, WH Hsu and HS Hsu. (2008). Reduced membranous beta-catenin protein expression is associated with metastasis and poor prognosis in squamous cell carcinoma of the esophagus. J Thorac Cardiovasc Surg 135:1029-1035.
56. Hildebrandt MA, H Yang, MC Hung, JG Izzo, M Huang, J Lin, JA Ajani and X Wu. (2009). Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 27:857-871.
57. Singh SK, C Hawkins, ID Clarke, JA Squire, J Bayani, T Hide, RM Henkelman, MD Cusimano and PB Dirks. (2004). Identification of human brain tumour initiating cells. Nature 432:396-401.
58. Chua C, N Zaiden, KH Chong, SJ See, MC Wong, BT Ang and C Tang. (2008). Characterization of a side population of astrocytoma cells in response to temozolomide. J Neurosurg 109:856-866.
59. Weber K, W Paulus and V Senner. (2010). The side population of gliomas exhibits decreased cell migration. J Neu-ropathol Exp Neurol 69:623-631.
60. Rosano L, R Cianfrocca, F Spinella, V Di Castro, MR Nicotra, A Lucidi, G Ferrandina, PG Natali and A Bagnato. (2011). Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res 17:2350-2360.
61. Brabletz T, A Jung, S Spaderna, F Hlubek and T Kirchner. (2005). Opinion-Migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer 5:744-749.
62. Lee K-W, J Kim, S Han, C-O Sung, I-G Do, Y-h Ko, S Um and S-H Kim. (2012). Twist1 is an independent prognostic factor of esophageal squamous cell carcinoma and associated with its epithelial-mesenchymal transition. Ann Surg Oncol 19: 326-335.
63. Zhang K, S Zhang, X Jiao, H Wang, D Zhang, Z Niu, Y Shen, L Lv and Y Zhou. (2011). Slug regulates proliferation and invasiveness of esophageal adenocarcinoma cells in vitro and in vivo. Med Oncol 28:1089-1100.
64. Kuo KT, TY Chou, HS Hsu, WL Chen and LS Wang. (2012). Prognostic significance of NBS1 and snail expression in esophageal squamous cell carcinoma. Ann Surg Oncol 19 Suppl 3:S549-S557.
65. Tomizawa Y, TT Wu and KK Wang. (2012). Epithelial mesenchymal transition and cancer stem cells in esophageal adenocarcinoma originating from Barrett's esophagus. Oncol Lett 3:1059-1063.
66. Peinado H, D Olmeda and A Cano. (2007). Snail, ZEB and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7:415-428.
67. Ohashi S, M Natsuizaka, GS Wong, CZ Michaylira, KD Grugan, DB Stairs, J Kalabis, ME Vega, RA Kalman, et al. (2010). Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res 70:4174-4184.
68. Burk U, J Schubert, U Wellner, O Schmalhofer, E Vincan, S Spaderna and T Brabletz. (2008). A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 9:582-589.
69. Wellner U, J Schubert, UC Burk, O Schmalhofer, F Zhu, A Sonntag, B Waldvogel, C Vannier, D Darling, et al. (2009). The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 11:1487-1495.